ORKA Oruka Therapeutics Inc.
Price (delayed)
$11.02
Market cap
$385.68M
P/E Ratio
N/A
Dividend/share
$19.36
EPS
-$6.26
Enterprise value
-$24.2M
Highlights
The company's quick ratio fell by 41% YoY and by 13% QoQ
Oruka Therapeutics's EPS has decreased by 41% YoY and by 4.3% from the previous quarter
Key stats
What are the main financial stats of ORKA
Market
Valuations
Earnings
Shares outstanding
35M
Market cap
$385.68M
Enterprise value
-$24.2M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.04
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$36.64M
Net income
-$34.4M
EBIT
-$33.9M
EBITDA
-$33.8M
Free cash flow
-$40.25M
Per share
Balance sheet
Liquidity
EPS
-$6.26
EPS diluted
-$6.26
Free cash flow per share
-$2.68
Book value per share
$283.2
Revenue per share
$0
TBVPS
$27.58
Total assets
$414.09M
Total liabilities
$18.88M
Debt
$988,000
Equity
$342.37M
Working capital
$394.91M
Debt to equity
0
Current ratio
22.89
Quick ratio
22.78
Net debt/EBITDA
12.13
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-15.2%
Return on equity
-18.1%
Return on invested capital
N/A
Return on capital employed
-8.6%
Return on sales
N/A
Dividend yield
175.65%
DPS
$19.36
Payout ratio
N/A
ORKA stock price
How has the Oruka Therapeutics stock price performed over time
Intraday
-2.3%
1 week
-1.43%
1 month
-15.1%
1 year
-43.66%
YTD
-43.17%
QTD
-43.17%
Financial performance
How have Oruka Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$36.64M
Net income
-$34.4M
Gross margin
N/A
Net margin
N/A
Growth
What is Oruka Therapeutics's growth rate over time
Valuation
What is Oruka Therapeutics stock price valuation
P/E
N/A
P/B
0.04
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Oruka Therapeutics's EPS has decreased by 41% YoY and by 4.3% from the previous quarter
ORKA's price to book (P/B) is 100% lower than its last 4 quarters average of 5764.8 and 100% lower than its 5-year quarterly average of 1214.2
Efficiency
How efficient is Oruka Therapeutics business performance
The return on equity has declined by 33% year-on-year but it has grown by 10% since the previous quarter
Oruka Therapeutics's return on assets has increased by 21% QoQ but it has decreased by 16% YoY
Dividends
What is ORKA's dividend history
DPS
$19.36
Dividend yield
175.65%
Payout ratio
N/A
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Oruka Therapeutics financials performed over time
The company's current ratio fell by 42% YoY and by 14% QoQ
The company's quick ratio fell by 41% YoY and by 13% QoQ
The company's debt is 100% lower than its equity
The company's debt to equity has shrunk by 100% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.